Artificial IP

In a May 2018 article in Nature, the authors wrote about how artificial intelligence is changing discovery of novel drugs compounds. The article noted how Pfizer, Sanofi, Genentech and others have all adopted AI approaches — including IBM’s Watson — to identify new drug compounds and novel structures for a variety of diseases. And the article urged scientists, academics and biology …

Please sign in to continue.

Become a valued Chicago Lawyer subscriber today and receive:

  • 6 bimonthly print editions mailed.
  • Access to and our e-edition.
  • Bimonthly news and informational emails.
  • Special editions such as Forty Under 40, Practice Resource Guides and much, much more!.

Call (312) 644-2394 or subscribe now.